DOPAMIN AGONISTLARI YORDAMIDA INDUKSIYA QILINGAN HOMILADORLIKLARDAN TUG‘ILGAN 6–12 YOSHLI BOLALARNING KLINIK-GORMONAL SALOMATLIGI
##article.subject##:
giperprolaktinemiya, prolaktinoma, dopamin agonistlari, homiladorlik, bolalar, gormonal holat.##article.abstract##
Dolzarblik: Giperprolaktinemiya va gipofizning prolaktin sekretsiya qiluvchi adenomalarі ayollarda reproduktiv funksiyaning buzilishiga olib keluvchi asosiy endokrin sabablar qatoriga kiradi. Bromokriptin va kabergolin kabi dopamin agonistlari prolaktin darajasini samarali pasaytirish, ovulyator siklni tiklash va homiladorlikka erishish imkonini beradi. Ushbu preparatlarning klinik samaradorligi va nisbatan xavfsizligi isbotlangan bo‘lsa-da, ularning prenatal ta’sirining bolalarda uzoq muddatli klinik-gormonal holatga ta’siri yetarli darajada o‘rganilmagan. Ayniqsa 6–12 yosh davri alohida ahamiyatga ega bo‘lib, bu davrda o‘sish jarayonlari va neyroendokrin regulyatsiya faol shakllanadi. Maqsad: Dopamin agonistlari yordamida induktsiyalangan homiladorlikdan tug‘ilgan 6–12 yoshli bolalarning klinik-somatik va gormonal holati bo‘yicha zamonaviy adabiyot ma’lumotlarini tahlil qilish. Materiallar va usullari: Giperprolaktinemiya, prolaktinoma, homiladorlikni rejalashtirish va homiladorlik davrida dopamin agonistlarini qo‘llash, shuningdek prenatal ta’sirga uchragan bolalarning jismoniy rivojlanishi va gormonal holatini baholashga bag‘ishlangan mahalliy va xorijiy ilmiy manbalar tahlil qilindi. Natijalar: Adabiyotlar tahlili shuni ko‘rsatadiki, ko‘pchilik tadqiqotlarda dopamin agonistlarini qabul qilgan onalardan tug‘ilgan bolalarda jismoniy rivojlanishning yaqqol buzilishlari va jiddiy gormonal og‘ishlar aniqlanmagan. Shu bilan birga, maktab yoshidagi bolalarda endokrin tizim holatini baholovchi ma’lumotlar cheklangan. Xulosa: Dopamin agonistlarining prenatal ta’sirining uzoq muddatli klinik-gormonal oqibatlari masalasi dolzarb bo‘lib qolmoqda va kelgusida chuqur ilmiy tadqiqotlarni talab etadi.
Библиографические ссылки
Aashikaa J. K., Mirkhmidova S. M. Prolactinoma in pregnancy and its treatment // Endokrinologiyaning dolzarb muammolari: Xalqaro ilmiy-amaliy anjumani materiallari to‘plami. – Toshkent: MChJ «Tibbiyot nashriyoti matbaa uyi», 2023. – P. 43.
Araujo B., Belo S., Carvalho D. Pregnancy and tumor outcomes in women with prolactinoma
// Hormone Research in Paediatrics. – 2023. – DOI: 10.1055/s-0043-112861.
Carvalho Santos A., Yela D. A., Nakamura R. M., et al. Does hyperprolactinemia treatment affect pregnancy and perinatal outcomes? // Archives of Endocrinology and Metabolism. – 2024. – PMID: 39536251.
Colao A., Abs R., Gonzalez-Barcena D., et al. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study // Clinical Endocrinology. – 2007. – DOI: 10.1111/j.1365-2265.2007.03000.x.
De Wit W., Coelingh Bennink H. J. T. Prophylactic bromocriptine treatment during pregnancy in women with macroprolactinomas // British Journal of Obstetrics and Gynaecology. – 1984. – DOI: 10.1111/j.1471-0528.1984.tb15076.x.
Dosanova A. K. Quality of life of patients with prolactinomas after various treatment methods
// Biomeditsina va amaliyot jurnali. – 2020. – №1. – P. 85–95.
Dosanova A. K., Bazarbekova R. B. Experience of conservative treatment of women with prolactinomas // Biomeditsina va amaliyot jurnali. – 2020. – №1. – P. 96–101.
Halimiova Z. Yu., Safarova M. S., Gumarova A. A., Jabborova G. M. Clinic and course of hyperprolactinemia in prolactinomas // Biomeditsina va amaliyot jurnali. – 2020. – SI 1. – P. 69–78.
Halimiova Z. Yu., Issaeva S. S. Pituitary adenomas: from diagnosis to therapy (review) // Vestnik assotsiatsii pulmonologov Tsentralnoy Azii. – 2024. – Vol. 2, №4. – P. 59–70.
Halimiova Z. Yu., et al. Evaluation of cabergoline efficacy in prolactinomas // Pediatriya. – 2018. – №2. – P. 144–147.
Halimiova Z. Yu., et al. Prolactinoma: clinical and diagnostic aspects // Pediatriya. – 2018. –
№2. – P. 140–144.
Halimiova Z. Yu., et al. Influence of cabergoline on metabolic syndrome in prolactin-secreting pituitary adenomas // Journal of Theoretical and Clinical Medicine. – 2017. – №6. – P.
–32.
Maiter D. Prolactinoma and pregnancy: from the wish of conception to lactation // Annales d’Endocrinologie. – 2016. – DOI: 10.1016/j.ando.2016.04.001.
Nasyrоva H. K. Features of pregnancy course in women with prolactinomas // Journal of Theoretical and Clinical Medicine. – 2018. – №5. – P. 92–96.
Nasyrоva H. K. Management of pregnant women with prolactinomas and pregnancy outcomes // Journal of Theoretical and Clinical Medicine. – 2019. – №3. – P. 107–110.
Nasyrоva H. K., Mukhammedaminova D. T., Halimiova Z. Yu. Epidemiology and management problems of prolactinomas // Biomeditsina va amaliyot jurnali. – 2020. – SI 1. –
P. 163–171.
O’Sullivan S. M., Farrant M. T., Ogilvie C. M., et al. Pregnancy and post-partum outcomes in women with prolactinoma treated with dopamine agonists // Australian and New Zealand Journal of Obstetrics and Gynaecology. – 2019. – DOI: 10.1111/ajo.13070.
Otis A.-S., Brochet M.-S., Tremblay Z., et al. Cabergoline use and pregnancy outcomes: a systematic review // Birth Defects Research. – 2025. – DOI: 10.1002/bdr2.2464.
Prencipe N., Bona C., Cuboni D., et al. Prolactin-secreting tumors, dopamine agonists and pregnancy // Journal of Endocrinological Investigation. – 2024. – PMID: 38499816.
Raymond J. P., Goldstein E., Konopka P., et al. Follow-up of children born of bromocriptine-treated mothers // Hormone Research. – 1985. – DOI: 10.1159/000180100.
Stalldecker G., Mallea-Gil M. S., Guitelman M., et al. Effects of cabergoline on pregnancy and embryo-fetal development // Pituitary. – 2010. – DOI: 10.1007/s11102-010-0243-6.
Shupik P. L., Roshchina G. F. Hyperprolactinemia and its consequences: modern concepts // Medical Express. – 2018. – №5. – P. 66.
